Phase 1 Study of CD30-Directed Genetically Modified Autologous T-Cells (CD30.CAR-T) in Patients With Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma
Latest Information Update: 24 Apr 2023
At a glance
- Drugs TT 11 (Primary) ; Bendamustine; Fludarabine
- Indications Anaplastic large cell lymphoma; Diffuse large B cell lymphoma; Extranodal NK-T-cell lymphoma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma
- Focus Adverse reactions
- Acronyms CERTAIN
- Sponsors Tessa Therapeutics
- 21 Jul 2022 Status changed from recruiting to active, no longer recruiting.
- 05 Mar 2021 Planned End Date changed from 1 Feb 2023 to 1 Mar 2036.
- 05 Mar 2021 Planned primary completion date changed from 1 Feb 2022 to 1 Mar 2023.